NCT07365904招募中2 期
A Single-centre, Open-label, Phase II Study on the Maintenance of Ovulation Inhibition After Intentional Application Contraceptive
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Ovulation incidence in cycle with regular application, and in cycles with extended period application errors. Ovulation is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.
研究概览
简要总结
A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR 130A 01 contraceptive transdermal patch
详细描述
Ovulation inhibition study of MR-130A-01 contraceptive transdermal patch containing norelgestromin with intentional application errors; MR-130A-01-TD-2002
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •1. Healthy, post-menarcheal and premenopausal women of age 18 to 35 years (inclusive) at screening examination.
- •2. BMI ≥18.0 kg/m2 at screening examination.
- •Participants must be in good physical and mental health as determined by vital signs, medical history, and physical and gynecological examination, as assessed by the investigator.
- •4. Written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the participant participating in the clinical trial.
- •5. Status at least 3 months after a delivery, abortion, and stopping lactation, if applicable, before screening.
- •6. Has regular menstrual cycles that are between 21 and 35 days in duration as reported by the participant during anamnesis, with an intact uterus and ovaries. If the participant uses hormonal birth control at screening, historic data should be used to evaluate this criterion.
- •7. Both ovaries must be visible on TVUS examination during screening.
- •Ovulatory pre-treatment cycle, as confirmed by a progesterone concentration >10.0 nmol/L.
- •9. Participants must consent to use reliable non-hormonal contraceptive methods (male condoms, diaphragm, or heterosexual abstinence) throughout the study, unless the participant has a history of female sterilization or sterilization of the sexual partner.
排除标准
- •1. Known hypersensitivity or intolerance to any ingredient of the investigational product.
- •2. History or presence of dermal sensitivity to medicated patches or to topical applications including bandages, surgical tape.
- •3. Pregnancy or a positive serum beta human chorionic gonadotropin (β-hCG) pregnancy test at screening.
- •4. Clinically relevant abnormal findings from serum biochemistry and hematology and HBsAG/ Hepatitis C virus/ human immunodeficiency virus (HIV) serology as evaluated by the investigator
- •ASAT (aspartate-aminotransferase) > 20 % upper limit of normal (ULN), ALAT (alanine-aminotransferase) > 10 % ULN, bilirubin > 20% ULN (except in case of existing Morbus Gilbert-Meulengracht deduced from anamnesis/medical history) and creatinine > 0.1 mg/dL ULN (limit of > 0.1 mg/dL corresponds to > 9 µmol/l ULN).
- •6. Use of a non-hormonal intra-uterine device within the pre-treatment cycle or any hormonal contraception as follows:
- •Short-acting hormonal contraceptives such as oral, patch, ring or intrauterine systems within the menstrual cycle prior to the pre-treatment cycle.
- •Injectable (intramuscularly or subcutaneously) within 10 months (three-month treatment duration), 6 months (two-month treatment duration) or 3 months (one-month treatment duration) prior to the start of pre-treatment cycle or implants within the menstrual cycle prior to the pre-treatment cycle.
- •7. Known or suspected malignancy or history thereof.
- •Unexplained vaginal bleeding within the past 6 months suspicious for serious condition, or any abnormal bleeding which is expected to recur during the study (e.g. bleeding from cervical polyp, recurrent bleeding after sex).
- •9. History or presence of ischemic heart disease, coronary artery disease, myocardial infarction, stroke, other cerebrovascular diseases including transient ischemic attacks (TIAs).
- •10. History or presence of hypertension or hypertension with vascular disease or elevated blood pressure (BP) defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg, measured in sitting position after at least 5 minutes of rest (a single reading of blood pressure level is not sufficient to classify a woman as hypertensive).
- •11. Pulse rate (PR) < 50 bpm or > 90 bpm
- •Presence of deep vein thrombosis/pulmonary embolism.
- •Has any comorbid condition that may require major surgery with prolonged immobilization during the study period.
- •14. Presence of liver disease including severe (decompensated) cirrhosis, benign (e.g., hepatocellular adenoma) or malignant liver tumors.
- •15. Chronic disease potentially necessitating organ transplantation during the anticipated course of the study.
研究组 & 干预措施
"regular": regular application without planned application errors
Experimental
干预措施: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) (Drug)
Extended Period 1: regular application with planned application errors
Experimental
干预措施: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) (Drug)
Extended Period 2: regular application with planned application errors
Experimental
干预措施: MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN) (Drug)
结局指标
主要结局
Ovulation incidence in cycle with regular application, and in cycles with extended period application errors. Ovulation is defined as a Hoogland-Skouby score 5 or 6 in combination with fulfilment of Landgren criterion.
时间窗: 84 days
次要结局
- Ovulation incidence overall and incidence per treatment cycle.(84 days)
- HSS determined for each treatment cycle.(84 days)
- Fulfilment of Landgren criterion in cycles with HSS 5 or 6.(84 days)
- FLS diameter and endometrial thickness determined by transvaginal ultrasound (TVUS).(84 days)
- Pituitary (luteinizing hormone [LH]) and ovarian (estradiol [E2], progesterone [P]) hormone concentrations in serum.(84 days)
- Plasma concentration of NGMN and its metabolite norgestrel Immediately 5min before and at the end of one scheduled patch-free window.(84 days)
- Plasma concentrations of NGMN and norgestrel.(84 days)
- Assessment of adhesion score by the participants themselves and by the site personnel.(84 days)
- Safety and tolerability: Treatment-emergent Adverse Events (TEAE) Safety clinical laboratory parameters Incidence of application site reactions (skin irritation scores assessed by the participants).(84 days)
- Bleeding pattern determined as Incidences of bleeding and/or spotting episodes. Number of observed days of bleeding and/or spotting, bleeding only and spotting only. Incidences of complete absence of bleeding or spotting (excluding the first episode).(84 days)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
4 期
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome2024-519354-36-00Amsterdam UMC Stichting816
招募中
1 期
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast CancerAdvanced Breast CancerEarly Breast CancerNCT07310420TerSera Therapeutics LLC176
招募中
4 期
RAndom sTArT Ovarian stimUlatIon (RSOS) in eLective oocyte cryopreservation cycLEs (RATATOUILLE): a single-center, non-inferiority, randomised controlled trial2023-509919-89-00UZ Brussel277
进行中（未招募）
不适用
Characterisation of ovulation inhibition and effects on parameters of the human body of multiple doses of a fixed-dose combination product containing 0.02 mg ethinylestradiol and 2 mg dienogest (hormons) in comparison to a marketed product containing 0.02 mg ethinylestradiol and 0.10 mg levonorgestrel in healthy females of childbearing potentialEUCTR2012-000041-12-NLZentiva k.s. Prague
已完成
2 期
Characterisation of ovulation inhibition and effects on metabolic parameters and haemostatic system of multiple administrations of a fixed-dose combination product containing 0.02 mg ethinylestradiol and 2 mg dienogest (24+4) in a multiple administration, comparative parallel-group trial vs. a marketed product containing 0.02 mg ethinylestradiol and 0.10 mg levonorgestrel with healthy females of childbearing potentialinhibition of ovulationhormonal contraceptionNL-OMON37701Zentiva k.s.60